November 02, 2018
1 min read

Patients achieve HDV RNA decline, negativity in Lambda phase 2 study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Results from a phase 2 study of Lambda for the treatment of hepatitis D showed a decline of HDV RNA in more than half of treated patients, according to a press release from Eiger BioPharmaceuticals.

“Lambda interferon demonstrated better tolerability in HDV-infected patients who were previously treated with alpha-interferon,” study co-lead investigators Ohad Etzion, MD, from Soroka University Medical Center, and Saeed Hamid, MD, from Aga Khan University, said in the release. “Fewer episodes of cytopenia, flu-like symptoms, and psychiatric events in this study make Lambda interferon particularly attractive for further development as a monotherapy or in combination with other treatments for HDV.”

The researchers randomly assigned 33 patients to receive 180 g (n = 16) or 120 g (n = 17) of Lambda (pegylated interferon lambda) with subcutaneous injections for 48 weeks.

At week 48, patients who received 180 g of Lambda achieved a mean HDV RNA decline of –2.4 log 10 with 60% experiencing a decline of 2 log 10 or more. At the end of treatment, 40% were HDV RNA negative.

In the 120 g group, patients achieved a mean HDV RNA decline of –1.5 log 10 with 42.9% of patients experiencing a decline of 2 log 10 or more and 14.3% achieving a negative HDV RNA status.

The most common adverse events included mild to moderate flu-like symptoms and elevated transaminase levels.

According to the release, Eiger plans to share additional details from the study during the AASLD 2018 meeting in San Francisco this November.